Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How are they making money if everyone is bailing?
SMOKE AND MIRRORS! If so many great things are happening, why are shares still being dumped?
I like how they misspelled his name right off the get go. Lol Marc must have been drunk when he drafted up this PR. And when you do a Google search for him he comes up as a fantasy writer/director lol perfect fit
He isn't making anywhere near that, read the conditions of the YAG agreement. His salary is being reduced until the debt is paid in full.
Yes this should be an interesting week, any idea when the next financials aredue oout?
Money has been tight, believe me if I had it I would have. And it takes a couple day for my funds to transfer.
Loading more shares Monday. Can't wait for this to boom.
Go CIRC!!!!!
Philip Verges is behind CCTR...and if you know anything about this guy, you will stay away from this stock. He just destroyed investors in another stock I own of his with a 1 for 20,000 reverse split.
Best advice for Philip Verges stocks...RUN AWAY AS FAST AS YOU CAN!!!
He is a man with no moral compass and contempt for shareholders.
My only hope is that by some miracle they can artificially raise the PPS of this piece of sh!t scam so I can recoup my losses.
This is funny, I wonder how so many inquiries were made when nobody can seem to contact the company lol
If this pos is being shorted, its game over. They won't stop until they can cover at no bid. Game over.
So you know a lot about the new CEO?
The news and filings are the same rhetoric, that's been copied and pasted over and over and resubmitted as viable information. Where's the uplisting that was supposed to happen in the end of January? Where are the audited financials that have been in work since at least November of last year, why can't the company be reached for comment? Where is the website? Why didn't they disclose the new CEO's name? Perhaps they don't wanna make liable false statements. Don't be fooled by these crooks.
NO GOLD
NO MINING OPERATIONS
NO CAPITAL
NO UPLISTING
NO AUDITED FINANCIALS
HOW MUCH PROOF DOES ONE PERSON NEED TO SEE THE SCAM BEFORE YOU. SIMPLE DD WILL SHOW THIS IS NOTHING MORE THAN HYPE.
STICK A FORK IN IT, ITS DONE
Lol more fluff PR, and some more UNAUDITED financials. Hell at this point is settle for some contact information, we don't need another ghost CEO lol
Bragging LOL you've been saying the same nonsense for months, and it dips finally and you assume you got all the answers sure bud
Let it hit .0003 ill buy even more, but we both know it wont. Hopefully it will though so you can cover, you gotta be getting nervous.
There's been a merger with aigi, the new ticker is now Alga, there has also been a 20,000-1 R/S which means you will have less then 2 shares when your broker issues your new shares
Don't forget about the infamous Photoshop mining facility picture that was used for the ibox
They have to put fictitious updates somewhere, they no longer have a website to do it from
Here's a lesson for you then my friend. You say "have to" as if you were asked to give a lesson. Where you should have used the words "decided to" I seem to recall a point in time where you volunteered the fact that you held no position in this stock, nor did you have a side you took. However I've yet to see any positive information come fromYour posts, so it peeks my interest as to why you are here if your not a shareholder of CIRC.
Yeah this R/S really put a sour taste in my mouth. But guess you gotta learn the ways by being there
Financials are out
financials
Another one lol, could you imagine? There would be a 150 pissed off investors looting the alga headquarters building
To me it looks like they are making changes, if you notice since may they have appointed a new chairman, legal fees have dropped a bit capital is up, over head and operational cost look to be down a bit. We may be looking at a turning point. I'm gonna dog into this one a bit more.
Thanks for the advice, I think ill watch it as well. Looks like a good bottom right now. But ill hold out
PURE Bioscience Reports Fiscal Third Quarter 2013 Results
MarketwiredPress Release: PURE Bioscience, Inc. –
SAN DIEGO, CA--(Marketwired - Jun 14, 2013) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, reported results for its fiscal third quarter ended April 30, 2013.
Fiscal Q3 2013 Highlights
•Initiated field testing of PURE® Hard Surface disinfectant with two major quick service restaurant chains, each with thousands of locations worldwide.
•Completed a 30-day in-plant product testing process with a major meat and poultry food processor that manages multiple processing plants across the U.S.
•Appointed food industry leader, Dave Pfanzelter, to the company's board of directors and subsequent to quarter-end appointed him chairman.
Fiscal Q3 2013 Results
Net product sales totaled $258,000, compared to $207,000 in the same quarter last year. The increase was primarily attributable to increased sales to two existing customers.
Total operating costs and expenses decreased $200,000 to $1.8 million, compared to $2.0 million in the same year-ago quarter. The decrease was primarily due to a decrease in legal fees, travel, non-cash stock option expense, and depreciation and amortization expense.
Loss from operations decreased $200,000 to $1.6 million, compared to a loss from operations of $1.8 million in the same year-ago quarter.
Net loss was $1.5 million or $(0.14) per share, an improvement from a net loss of $1.8 million or $(0.31) per share in the same quarter last year.
As of April 30, 2013, cash and cash equivalents totaled $410,000 and current liabilities totaled $1.5 million, including accounts payable of $848,000. The company intends to secure additional working capital through sales of additional debt or equity securities.
Management Commentary
"During the quarter, we significantly cut costs and streamlined our operations to improve our bottom line, while making progress with key sales opportunities that should position us for sustainable growth," said Michael L. Krall, president and CEO of PURE Bioscience. "Our sales and marketing projects during the quarter included coordinating field testing of PURE Hard Surface disinfectant and sanitizer in two different quick service restaurant chains, working with multiple meat and poultry food processors to conduct in-plant testing, and ongoing evaluations by several hospitals.
"Addressing the international opportunity, we recently shipped an opening order of PURE Hard Surface and PURE Multi-Purpose cleaner concentrate to our new European distributor, TICE. We are seeing progress with all of our target customer groups and remain optimistic that our marketing, education, evaluation and field testing programs could convert to meaningful sales in the second half of calendar 2013."
During the second half of 2013, the company intends to submit a notification of GRAS determination to the U.S. FDA for its review under the GRAS standards (Generally Recognized As Safe) for use of the SDC technology as a direct food contact antimicrobial (processing aid) and secondarily as a preservative (food additive). The additional GRAS claims for SDC are designed to expand its potential commercial adoption for direct use on produce and meats. The company has already obtained GRAS status for SDC when used on food processing facilities, equipment, machinery, and processing utensils. The FDA's stated goal is to respond within 180 days of the initial notification submission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA), Human Corona Virus and Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-Looking Statements
This press release contains forward-looking statements in which the Company discusses its potential future performance. Forward-looking statements are all statements other than statements of historical facts, such as those statements regarding the Company's anticipated capital requirements, future financing activities, future submissions to the FDA related to its technologies and anticipated timing of commercialization of its technologies. The words "believe," "anticipate," "intend," "estimate," "project," "expect" and similar expressions are intended to identify those assertions as forward-looking statements. The Company cautions readers that forward-looking statements are not guarantees of future performance and its actual results may differ materially from those anticipated, projected or assumed in the forward-looking statements. Important factors that could cause the Company's actual results to differ materially from those anticipated in the forward-looking statements include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed initiatives and business plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks described in more detail under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2012, filed with the SEC, as updated by its subsequent filings with the SEC, including its Quarterly Reports on Form 10-Q. Investors are cautioned that many of the assumptions on which the Company's forward-looking statements are based are likely to change after its forward-looking statements are made. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Pure Bioscience, Inc.
Condensed Consolidated Balance Sheets
April 30, July 31,
2013 2012
(Unaudited)
Assets
Current assets
Cash and cash equivalents $ 410,000 $ 877,000
Accounts receivable, net 29,000 373,000
Inventories, net 781,000 654,000
Prepaid expenses 110,000 347,000
Total current assets 1,330,000 2,251,000
Property, plant and equipment, net 171,000 257,000
Patents, net 2,004,000 1,950,000
Total assets $ 3,505,000 $ 4,458,000
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 848,000 $ 1,946,000
Loan payable, net - 962,000
Deferred revenue - 66,000
Note payable, current 231,000 -
Accrued liabilities 411,000 344,000
Derivative liability 49,000 319,000
Total current liabilities 1,539,000 3,637,000
Note payable, less current portion 1,045,000 -
Deferred rent 15,000 3,000
Total liabilities 2,599,000 3,640,000
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued - -
Common stock, $0.01 par value: 100,000,000 shares authorized 12,236,170 issued and outstanding at April 30, 2013, and 6,644,555 issued and outstanding at July 31, 2012. 123,000 67,000
Additional paid-in capital 68,795,000 63,251,000
Accumulated deficit (68,012,000 ) (62,500,000 )
Total stockholders' equity 906,000 818,000
Total liabilities and stockholders' equity $ 3,505,000 $ 4,458,000
Pure Bioscience, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
Nine months ended Three months ended
April 30, April 30,
2013 2012 2013 2012
Net product sales $ 631,000 $ 685,000 $ 258,000 $ 207,000
Operating costs and expenses
Cost of goods sold 155,000 206,000 67,000 37,000
Selling, general and administrative 4,550,000 5,439,000 1,464,000 1,557,000
Research and development 1,105,000 1,421,000 304,000 439,000
Total operating costs and expenses 5,810,000 7,066,000 1,835,000 2,033,000
Loss from operations (5,179,000 ) (6,381,000 ) (1,577,000 ) (1,826,000 )
Other income (expense)
Change in derivative liability 270,000 - 30,000 -
Interest expense (591,000 ) - (2,000 ) -
Interest income - 1,000 - -
Other (expense) income, net (12,000 ) (3,000 ) 15,000 (3,000 )
Total other (expense) income (333,000 ) (2,000 ) 43,000 (3,000 )
Net loss $ (5,512,000 ) $ (6,383,000 ) $ (1,534,000 ) $ (1,829,000 )
Basic and diluted net loss per share $ (0.53 ) $ (1.18 ) $ (0.14 ) $ (0.31 )
Shares used in computing basic and diluted net loss per share 10,310,721 5,400,685 11,255,833 5,838,466
.
.
Contact:.
.
Investor Relations
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
I see, so not worth putting cash on then.
An R/S on 10 mill O/S? I must be missing something.
Not a lot of eyes on this stock. I like it
Seeing some movement today
Quarterly don't look too bad, anyone got any info on this company worth sharing
Well the in favors have allowed continued use of the trade mark, so some judge somewhere obviously agrees with Cirtran.
True however you forgot mention that every ruling to date has been in favor of Cirtran, lets get all the information out there.
GO CIRC!
No dumping going on here. Just flippers
GO CIRC!!!
But, but, but their uplisting and their in the process of getting audited financials, soon real soon they will be current, and the new management team is taking the company in a new direction. Pretty soon they will have a new Photoshoped picture of the mining setup and like 50 joint ventures in play, and I bet then they will do a share buyback program. Things are looking great for us stuck holders I mean share holders in this magnificent company Lmao (then they woke up)
Lol ill answer for him, its a hoax. The CEO faked all of it remember?
Thanks. That needs to be put in the ibox, mods?
Hw, can you post the actual text. Imvat work and I can't read it from the site for some reason, thanks
Sure they do, their buying tons of pbed from Cirtran. They may not be partnered with them, but they are buying massive amounts of a product that is manufactured by Cirtran, which is creating revenue. So what point are you trying to make here?
Lol yep nobody saw this coming GDSM=SCAM, no fluff PR will ever be enough to hide the facts. Do your DD and you will see the absolute scam unfolding. Its not even a well orchestrated one. Marc is laughing all the way to the bank. Stuck stay stuck, and new unknowing investors join the many that have already watched this P.O.S. tank
Of course this is just my humble opinion. Lol